(Q35170935)

6 August 2017

1 reference

title

Novel therapeutic approaches for multiple myeloma (English)

1 reference

6 August 2017

Paul Richardson

1 reference

6 August 2017

Kenneth C Anderson

1 reference

6 August 2017

Teru Hideshima

1 reference

6 August 2017

publication date

1 August 2003

1 reference

6 August 2017

published in

Immunological Reviews

1 reference

6 August 2017

volume

194

1 reference

6 August 2017

page(s)

164-176

1 reference

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Myeloma and the newly diagnosed patient: a focus on treatment and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Apoptosis in multiple myeloma: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Plasma cell differentiation requires the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

A molecular compendium of genes expressed in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Interleukin-21 is a growth and survival factor for human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

How proteolysis drives the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Current status of clinical trials of farnesyltransferase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Tumor Necrosis Factor-α Induces Interleukin-6 Production and Integrin Ligand Expression by Distinct Transduction Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

The role of interleukin-1 beta in the pathogenesis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl‐2 oncoprotein

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2003.00053.X

7 January 2021

10.1034/J.1600-065X.2003.00053.X

Identifiers

DOI

1 reference

6 August 2017

1 reference